Extract

The purpose of this study is to compare progression free survival for SU011248 [sutent (sunitinib malate)] versus standard of care therapy in patients with previously treated, advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast cancer.

Inclusion criteria

• Breast Neoplasms

Country

• Bulgaria
• Canada
• Czech Republic
• France
• Germany
• Hungary
• Italy
• Spain
• Turkey
• Ukraine
• United Kingdom
• United States

Links

• ictrp
• nct